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1. Introduction 
Phospholipid metabolism is thought o play a key 
role in the activation of a wide variety of cell types 
[1,2]. In platelets, arachidonate is released from 
membrane phospholipids [3] and subsequently con- 
verted to thromboxane A2, a potent inducer of plate- 
let aggregation and secretion [4]. In addition, one or 
possibly more thromboxane-independent mechanisms 
of platelet activation exist which also appear to 
involve phospholipid metabolism [5,6]. In response 
to thrombin [7,8] and to collagen [7], platelet phos- 
phatidylinositol is degraded by phopholipase C with 
the formation of diglyceride [9] and subsequently 
phosphatidic acid [10]. The mechanism by which 
these events are coupled to secretion and aggregation 
is not clear, although it has been postulated that the 
phosphatidylinositol effect may be associated in some 
way with a rise in cytosol calcium concentration [1]. 
We have shown that secretion of 5-hydroxytrypt- 
amine in platelets can be triggered by the addition of 
strontium ions [ 11 ], possibly by mimicking a rise in 
intracellular calcium. We report here that strontium 
ions cause a specific turnover of the platelet phospha- 
tidylinositol pool accompanied by an apparent stimu- 
lation of polyphosphoinositide m tabolism. The lat- 
ter class of phospholipids is also thought o be involved 
in the regulation of cell activation during stimulation 
and may thus play a role in the control of granule 
secretion and other processes which occur during 
aggregation. 
2. Materials and methods 
Platelet-rich plasma was prepared as in [11 ] 
and incubated at 37°C for 2 h with [l(3)-aH]glyc - 
erol (Amersham; 100/.tCi/109 platelets) or with 
[5,6,7,8,9,11,12,14,15-3H] arachidonic acid (Amersham 
5/aCi/109 platelets). Platelets were then isolated by 
centrifugation and resuspended in 15 mM Tris-HC1, 
140 mM NaC1 buffer (pH 7.4) [11] at a 5 × 10S/ml. 
Aliquots (1 ml) of platelet suspension were incubated 
at 37°C and lipids subsequently extracted with 3 ml 
CHCla:MeOH: 13 N HC1 (200:100:1). The upper 
phase was re-extracted with 2 ml CHCI3 and the 
organic phases pooled and dried in a vacuum oven. 
Phospholipids were separated by 2-dimensional TLC 
as in [12] and neutral lipids by a unidirectional TLC 
method using ether:hexane:acetic acid (70:30:1) as 
solvent. Lipid spots were stained with iodine vapour, 
the spots scraped and counted for radioactivity fol- 
lowing the addition of 2 ml MeOH and 10 ml Bray's 
scintillant. 
3. Results and discussion 
When platelets labelled with [3H]glycerol were 
incubated in the presence of 8 mM SrC12, radioactiv- 
ity was lost from phosphatidylinositol with a maxi- 
mum effect at ~10 min (fig.la). Platelets labelled 
with [all] arachidonic acid, which is incorporated 
more effectively than glycerol into phosphatidyl ser- 
ine [13], showed a similar though less marked loss in 
radioactivity from this phospholipid in the presence 
of 8 mM SrC12 (fig.2a). No comparable changes in 
radioactivity were observed in phosphatidylcholine, 
phosphatidylethanolamine, phosphatidic acid or lyso- 
phosphatidylcholine spots (table 1). Similarly, no 
changes were found in radioactivity associated with 
diglyceride or monoglyceride (not shown) suggesting 
that SrCI: was not acting via activation of phospho- 
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Fig.1. Effect of 8 mM SrCI 2 on radioactivity associated with 
phosphatidylinositol (a)and polyphosphoinositides/lyso- 
phosphatidylinositol (b). Platelets were prelabelled with [ 3 H l- 
glycerol. Each value represents he mean of duplicate deter- 
minations; all experiments were performed at least 3 times 
with essentially similar results. 
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Fig.2. Effect of 8 mM SrCI~ on radioactivity associated with 
phosphatidylinositol (t)  phosphatidyl serine (o) and poly- 
phosphoinositides/lysophosphatidylinositol (m). Platelets 
were prelabelled with [3H]arachidonic a id. Each value rep- 
resents the mean of duplicate determinations; all experiments 
were performed at least 3 times, with essentially similar 
results. 
Table 1 
Effect of SrCI~ on radioactivity associated with the principal 
phospholipid spots in platelets pre-labelled with [3H]glycerol 
Incubation cpm/5 X 10 s platetets 
10 rain 
PI PPI/LPI PC PE PA LPC 
Saline 4146 580 5113 1309 59 363 
SrCI~,2mM 3589 738 5111 1188 77 280 
SRC12,4 mM 2871 1748 4625 1136 75 295 
SRC12,8 mM 2621 2280 4713 1140 80 271 
Abbreviations: PI, phosphatidylinositol; PPI, polyphospho- 
inositides; LPI, lysophosphatidylinositol; PC, phosphatidyl- 
choline; PE, phosphatidylethanolamine; PA, phosphatidic 
acid; LPC, lysophosphatidylcholine 
Each value represents he mean of duplicate determinations; 
each experiment was performed at least 3 times 
lipase C, This indirectly implies that arachidonate for 
production of thromboxane B2 is released in response 
to SrC12 via the activation of a phospholipase A~, pos- 
sibly the enzyme corresponding to the activity 
reported to release arachidonate from phosphatidyl- 
inositol and phosphatidylserine i  response to throm- 
bin [3]. Here, we were unable to determine which of 
these phospholipids is the major source of released 
arachidonate. 
The loss of radioactivity from phosphatidylinositol 
produced by SrC12 was associated with an increase in 
radioactivity in a spot which co.chromatographed 
with diphosphatidylinositol, triphosphatidylinositol 
and lysophosphatidylinositol (fig.l). A similar accu- 
mulation of radioactivity was observed in this spot 
whether using platelets labelled with [3H]glycerol r 
[3tt]arachidonic a id (fig.2). Since arachidonate is 
esterified almost exclusively in the 2 position of the 
89 
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Table 2 
Effects of various drugs and inhibitors on changes in PI and 
PPI labelling in response to 8 mM SrC12 
Incubation cpm/5 × 10 8 platelets 
10 min 
PI PPI 
Saline 6336 456 
SrCI 2, 8 mM 4387 2216 
+ CaCI~, 8 mM 6468 892 
+ 10 #g PGE1/ml 5598 864 
+ Indomethacin, 20/aM 5708 904 
+ Aspirin, 100 uM 6207 844 
+ Imidazole, 5 mM 4480 2392 
Each value represents he mean of duplicate determinations; 
each experiment was performed at least three times 
play a role in modulating secretion in platelets 
remains to be ascertained. If so, it seems likely that 
compounds such as aspirin and indomethacin may be 
able to affect platelet reactivity by inhibiting phos- 
pholipid metabolism in addition to the actions of 
these drugs upon prostaglandin production [ 18]. 
The use of Sr 2+ as a potential calcium probe may 
provide useful information concerning the role of 
Ca 2. in modulating secretory responses in platelets 
and other cell types during stimulation. Our results 
suggest that one likely role of Ca 2÷ in platelet func- 
tion may be in regulating the turnover and intercon- 
version of inositol phospholipids. 
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